Full-Time

Quality Systems Specialist 2

Element Science

Element Science

51-200 employees

Wearable defibrillator for sudden cardiac arrest

Compensation Overview

$87k - $100k/yr

+ Annual Bonus + Stock Options

No H1B Sponsorship

Redwood City, CA, USA

In Person

Relocation assistance is not offered.

Bachelor's

Category
Manufacturing Quality & Test (1)
Required Skills
Data Analysis

Get referred to Element Science

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific or engineering discipline or related discipline.
  • At least 3 years of relevant experience in a medical device environment with a focus on quality systems.
  • Strong knowledge of the current ISO 13485 standard and Quality Management System Regulation.
  • The ability to collaborate with cross-functional teams and provide guidance and input on quality initiatives.
  • Strong organizational skills, including the ability to manage multiple tasks, prioritize effectively, and meet deadlines in a fast-paced environment.
  • Strong problem-solving and analytical skills, including the ability to interpret data and make informed decisions.
  • The ability to work independently and take ownership of tasks while collaborating with others to meet common goals.
  • Prior experience preparing for or leading an internal, external, or regulatory audit.
Responsibilities
  • Support Corrective and Preventive Action processes by facilitating investigations, tracking progress, and ensuring corrective and preventive actions are implemented effectively.
  • Perform investigations for quality-owned Corrective and Preventive Actions, analyze root causes, and identify corrective and preventive actions.
  • Work with Manufacturing Engineering, Quality Engineering, Regulatory Affairs, Research and Development, and Production teams to support quality initiatives and ensure compliance with Quality Management System requirements.
  • Review Engineering Change Orders as a Quality Subject Matter Expert, provide feedback and guidance on the impact of changes, and help ensure changes comply with internal procedures and regulatory standards.
  • Assist with the review, routing, and approval of Quality Management System documentation, ensuring records are accurate, complete, and compliant with regulatory and quality standards.
  • Follow up with stakeholders to ensure timely approval and completion of documentation tasks.
  • Provide guidance and support to team members and peers on understanding and following Quality Management System processes.
  • Assist with training activities and contribute to continuous learning and improvement.
  • Collect, analyze, and report key quality metrics related to complaints, non-conformance reports, Corrective and Preventive Actions, and other Quality Management System processes.
  • Track trends and provide insights to identify process improvement opportunities.
  • Support internal and external audits, ensure compliance with ISO 13485, Quality Management System Regulation, and other applicable regulations, support resolution of audit findings, and help implement corrective actions.
  • Support DME/CHAP quality documentation requirements as applicable to the company's distribution model.
  • Assist with Post-Market Surveillance activities and track and analyze product performance data to identify potential quality issues or trends.
  • Lead or participate in quality improvement initiatives, identify process optimization opportunities, and support implementation of changes to enhance quality performance.
  • Perform other tasks as assigned by management.
Desired Qualifications
  • Experience with Propel or a similar electronic Quality Management System platform is strongly preferred.
  • Excellent written and verbal communication skills, including the ability to clearly explain and assist others with Quality Management System processes and requirements.

Element Science creates medical devices to prevent sudden cardiac arrest. Its flagship product, Jewel, is a wearable external defibrillator intended to provide around-the-clock protection by monitoring the heart and delivering a life-saving shock when needed. Jewel is not yet commercially available in the U.S. This device works by continuously monitoring cardiac rhythm and, if a dangerous rhythm is detected, delivering a controlled electrical defibrillation; it is designed for use by at-risk individuals under medical guidance. The company differentiates itself by focusing on a wearable, user-friendly defibrillator and by prioritizing workforce diversity, equity, inclusion, and belonging (DEIB), as well as growth through team expansion. Element Science aims to bring Jewel to market, work with healthcare providers and insurers, increase accessibility for patients at risk of sudden cardiac arrest, and grow its market share while reducing deaths from cardiac events.

Company Size

51-200

Company Stage

Series C

Total Funding

$183.1M

Headquarters

San Francisco, California

Founded

2013

Get referred to Element Science

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Element Science hired four executives on August 26, 2026 to accelerate commercialization.
  • Fast Company named Element Science among 2026’s World’s Most Innovative Companies.
  • Pivotal Jewel data showed high compliance and no deaths or serious device-related adverse events.

What critics are saying

  • Jewel remains commercially available only in limited U.S. markets as of August 2026.
  • ZOLL LifeVest still dominates wearable defibrillators, crushing adoption and pricing leverage.
  • Kestra Medical’s July 2026 $200 million financing intensifies competition and strains Element’s launch window.

What makes Element Science unique

  • Jewel uses an adhesive patch, not a bulky vest, improving wear time.
  • FDA approved Jewel on April 30, 2025; CE and UKCA arrived in January 2024.
  • Element Science combines machine-learning detection with clinical-grade wearables for sudden cardiac arrest.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

FSA (Flexible Spending Accounts)

HSA (Health Savings Account)

Employee Assistance Program through PEO

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-2%

2 year growth

-3%
FinancialContent
Aug 26th, 2026
Element Science expands executive leadership team to accelerate commercial growth and execution.

Element Science expands executive leadership team to accelerate commercial growth and execution. Published at August 26th 2026, 9:00 AM EDT via Business Wire i This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Key leadership hires bring deep medtech scaling expertise to advance the Jewel Patch Wearable Cardioverter Defibrillator Element Science, a pioneering health technology company and creator of the Jewel(R) Patch Wearable Cardioverter Defibrillator (Patch-WCD) to monitor and protect patients at high-risk of sudden cardiac arrest (SCA), today announced several strategic appointments to its executive leadership team. These key hires bring extensive industry experience across commercial strategy, operations, finance, and human resources to drive the company's next phase of growth. Paul Mandina, Element Science, Chief Revenue Officer "Element Science is entering an exciting new phase as we build the organization to support the commercialization of the Jewel Patch, and position the company for its next stage of growth," said Doug Devine, Chief Executive Officer of Element Science. "These appointments reflect our continued investment in building a world-class leadership team with the expertise needed to execute our strategy. Paul, Mark, Eric and Cheeka each bring proven track records from some of the medtech industry's most successful companies. Together they bring decades of experience scaling innovative companies, and will strengthen our ability to execute, innovate and expand access to Jewel, while advancing our mission to redefine care for patients at risk of sudden cardiac arrest." Executive Appointments * Paul Mandina, Chief Revenue Officer Paul brings more than 20 years of medtech commercial leadership experience. Most recently, he served as VP of U.S. Sales at Medtronic, where he led a $500 million portfolio to double-digit growth. Having previously built and scaled teams at Nevro, St. Jude Medical, and Intuitive Surgical, Mandina will shape Element Science's commercial strategy and build capabilities for market expansion. * Mark Hughes, Chief Operating Officer Mark joins Element Science from iRhythm, where he spearheaded operations through major commercial scaling. He brings deep manufacturing and supply chain expertise essential to guiding Element Science into early U.S. commercialization. * Eric Samuels, Chief Financial Officer Eric assumes the CFO role with extensive financial and operational experience from previous leadership roles at iRhythm and Intel. He will oversee the expansion of Element Science's financial and operational foundation to support long-term corporate growth. * Cheeka Trikha, Head of People and Organization Cheeka joins from Cognite, where she led People Business Partnering, following senior HR leadership roles at SAP, iRhythm, Confluent and Cognite. She brings a strong blend of medtech experience and organizational scaling expertise as Element Science continues to grow its talent base. This is an exciting time at Element Science. Following our recognition by Fast Company as one of the World's Most Innovative Companies of 2026, we're continuing to build the team and capabilities to advance our mission and shape the future of cardiac care. About Element Science, Inc. Element Science, Inc. is a medical device and digital health company focused on developing solutions at the intersection of clinical-grade wearables, machine learning algorithms, and lifesaving[1] therapies that address leading causes of death and hospitalization in patients with heart disease, primarily as they transition from the hospital-to-home. By putting the needs of patients and physicians first, our personalized digital devices, which are designed for function, comfort, and ease-of-use, aim to redefine the paradigm of care for these patients. Our first product, the Jewel Patch Wearable Cardioverter Defibrillator, is initially targeted at treating more than 850,000 patients in the U.S. and Europe with an elevated temporary risk of potentially experiencing a lethal heart rhythm. Based in San Francisco, our investors include Third Rock Ventures, Google Ventures, Deerfield Management, Qiming Venture Partners USA, Cormorant Asset Management, Boston Scientific and Invus Opportunities. Important Safety Information The Jewel Patch Wearable Cardioverter Defibrillator is a prescription device. The Jewel Patch Wearable Cardioverter Defibrillator is indicated for patients 18 years of age and older who are at risk for sudden cardiac arrest and are not candidates for or refuse an implantable defibrillator. For complete indications, contraindications, warnings, precautions and adverse events, see https://elementscience.com/manuals/. [1] Hummel, J. etc al, Jewel IDE Study, JACC, 2024 Aug, 84(6) 525-536 Contacts. Media Contact: Meredith Vornholt Element Science, Inc. 415-872-6500 | [email protected] Report this content If you believe this article contains misleading, harmful, or spam content, please let us know.

Business Wire
Mar 24th, 2026
Element Science named one of the world's most innovative companies by Fast Company

Element Science, a San Francisco-based health technology company, has been named to Fast Company's World's Most Innovative Companies of 2026 list. The company developed the Jewel Patch Wearable Cardioverter Defibrillator, which monitors and protects cardiovascular patients from sudden cardiac arrest. The Jewel Patch-WCD received FDA approval in April 2025 and European CE mark certification in January 2024. The device is water-resistant, discreet and requires no daily maintenance, distinguishing it as the only wearable cardioverter defibrillator that can be worn whilst showering. The product is currently in early commercial launch across select US states, targeting over 500,000 patients in the US and Europe at temporary risk of sudden cardiac arrest. Element Science's investors include Third Rock Ventures, Google Ventures and Deerfield Management.

Valdosta Daily Times
Jul 8th, 2024
Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel(R) Patch Wearable Cardioverter Defibrillator

Element Science, an innovative health technology company pioneering a digital wearable platform that monitors and protects high-risk cardiovascular patients, announces that its Jewel(R) Wearable Patch Cardioverter Defibrillator (Jewel) has received the prestigious Red Dot Design Award.

Business Wire
May 15th, 2024
Element Science Appoints Lee Smith, Jr. As The Company'S First Head Of Commercial

With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company's first Head of Commercial

Business Wire
Jan 25th, 2024
Element Science Receives Ce Mark Ukca Mark For The Jewel® Patch-Wearable Cardioverter Defibrillator

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs. While these garment-based WCDs have demonstrated the ability to treat sudden cardiac arrest (SCA), a leading cause of death in the United States and in Europe, challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption.The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, conducted in Prague, Czech Republic, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients presented at the American Heart Association’s 2023 Annual Scientific Sessions demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device (www.ElementScience.com/ide-study/ ).Dr. Uday N